|View printer-friendly version|
|November 01, 2017 4:20 p.m.|
|Teva Announces Completion of PARAGARD® Divestiture to CooperSurgical|
Closures mark first completion of planned divestiture of non-core assets to enable greater focus on core Specialty therapeutic areas of CNS and Respiratory
“With completion of the sale of PARAGARD®, Teva demonstrates
strong execution of our strategic divestiture plan,” stated Dr.
Teva continues to progress and actively pursue additional divestiture
opportunities, including the previously announced agreements for the
sale of Plan B One-Step® and the remaining assets of its
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the completion of the PARAGARD® divestiture which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
Teva Pharmaceutical Industries Ltd.